A Multicenter, Randomized, Double-Blind, Vehicle-Controlled Phase II Study to Evaluate the Efficacy, Tolerability, and Safety of VBP-245 in Pediatric Subjects for the Treatment of Molluscum Contagiosum
Phase of Trial: Phase II
Latest Information Update: 12 Dec 2017
At a glance
- Drugs VBP 245 (Primary)
- Indications Molluscum contagiosum
- Focus Therapeutic Use
- Sponsors Veloce BioPharma
- 01 Dec 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2018.
- 01 Dec 2017 Planned primary completion date changed from 1 Oct 2017 to 1 Oct 2018.
- 27 Mar 2017 New trial record